- Home
- ASMB vs DPG Comparison
ASMB vs DPG Comparison
Compare ASMB & DPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ASMB | DPG |
|---|---|---|
| Founded | 2005 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 442.9M | 525.1M |
| IPO Year | 2010 | 2011 |
Fundamental Metrics
Financial Performance| Metric | ASMB | DPG |
|---|---|---|
| Price | $31.91 | $14.40 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $44.20 | N/A |
| AVG Volume (30 Days) | ★ 119.5K | 73.2K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.78 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $638.39 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.13 | $12.00 |
| 52 Week High | $39.71 | $15.15 |
Technical Indicators
Market Signals| Indicator | ASMB | DPG |
|---|---|---|
| Relative Strength Index (RSI) | 64.78 | 41.91 |
| Support Level | $31.51 | $14.37 |
| Resistance Level | $32.44 | $14.73 |
| Average True Range (ATR) | 1.52 | 0.20 |
| MACD | 0.41 | -0.04 |
| Stochastic Oscillator | 99.83 | 11.69 |
Price Performance
Historical ComparisonAbout ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
About DPG Duff & Phelps Utility and Infrastructure Fund Inc.
Duff & Phelps Utility & Infrastructure Fund Inc. is an investment fund, and its objective is to seek total return, derived mainly from a high level of current income, with an emphasis on providing tax-advantaged dividend income and growth in current income, and secondarily from capital appreciation.